SIGA - SIGA Technologies, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.75
+0.07 (+1.05%)
As of 12:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.68
Open6.72
Bid6.78 x 1000
Ask6.80 x 1000
Day's Range6.61 - 6.80
52 Week Range2.90 - 8.47
Volume33,425
Avg. Volume337,764
Market Cap534.331M
Beta0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    SIGA Technologies to Host Business Update Webcast on September 27, 2018

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, September 27, 2018. A live webcast will be available on the Company's website, www.SIGA.com, under the 'Events & Presentations' tab in the Investor Relations section. Participants may also call (877) 407-6184 (United States/Canada) or (201) 389-0877 (International) and request the SIGA Technologies call or provide confirmation code 13683284.

  • GlobeNewswire7 days ago

    SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, September 14, 2018. “To date 2018 has been a historic year for SIGA and we are pleased to have the opportunity to recognize our multiple achievements as we ring the Nasdaq opening bell,” said Phil Gomez, CEO of SIGA Technologies. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.

  • GlobeNewswire10 days ago

    SIGA Technologies Awarded BARDA Contract for TPOXX®

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the delivery of oral and intravenous (IV) formulations of TPOXX® to the Strategic National Stockpile. The contract also covers advanced development of the IV formulation and post-marketing activities for the oral formulation of TPOXX. The contract (HHSO100201800019C) is valued at up to $629 million, and consists of a five-year base period of performance and a total contract period of performance (base period plus option exercises) of up to ten years (if necessary).

  • Benzinga2 months ago

    Siga Continues Rally After FDA Approves Smallpox Drug

    Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.

  • GlobeNewswire2 months ago

    U.S. Food and Drug Administration Approves SIGA Technologies’ TPOXX® (tecovirimat) for the Treatment of Smallpox

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication.

  • MarketWatch2 months ago

    SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy

    SIGA Technologies Inc. (SIGA) rose 9.6% in Friday afternoon trade on the Food and Drug Administration's approval of its TPOXX, the first-ever smallpox therapy. The contagious and often-deadly disease -- described as "one of the world's most devastating diseases known to humanity" by the World Health Organization -- has been considered eradicated since 1980 due to global immunization, but there have been fears that it could be used for bioterrorism, the FDA said. To establish the product's safety, it was tested in 359 healthy humans who did not have smallpox, while the efficacy findings that the approval was based on were in animals.

  • GlobeNewswire3 months ago

    Pivotal Trial Data for SIGA Technologies’ Oral TPOXX® Published in the New England Journal of Medicine

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, which comprises countermeasures for biological, chemical, radiological and nuclear attacks as well as vaccines and therapies for emerging infectious diseases and health preparedness to address serious unmet medical needs, today announced the publication of data in the New England Journal of Medicine from its pivotal human safety and animal efficacy studies of its oral formulation of TPOXX® (tecovirimat).  These results support the antiviral activity and favorable safety profile of TPOXX for the treatment of smallpox. “Smallpox is both highly contagious and highly lethal and there is growing concern that smallpox could be used as a potential bioweapon,” said Phil Gomez, PhD, SIGA’s Chief Executive Officer.

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...

  • ACCESSWIRE7 months ago

    Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018

    NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment ...